Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $8

Benzinga · 05/12/2025 17:09
Goldman Sachs analyst Andrea Tan maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $16 to $8.